JD Vance Predicts: Wall Street vs. Trump & Your Money

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Frank Joseph Daugherty net worth and biography

Frank Daugherty Biography and Net Worth

Insider of Greenwich LifeSciences

Dr. Daugherty has over 35 years of experience in managing and overseeing biotechnology and biomedical projects. Currently, he is Managing Partner of Phenolics, LLC and PharmaPrint, LLC, both of which are nutraceutical companies, and sits on the boards of several startup companies and a charitable foundation. Dr. Daugherty served first as President, and recently as Chief Executive Officer, Chief Medical Officer and the Chairman of the board of directors of Eleos, Inc., a clinical-stage, private biotech company focused on anti-sense technology in cancer. In addition to being an officer and director, Dr. Daugherty has served in various other capacities, including as a management consultant to over 20 public and private biomedical companies, like Dupont, Inc, and as President of ConAgra’s biotech division. He received a BA in Biology from Washington University, an MD from the University of Nebraska Medical Center, and an MS in Industrial Administration from Carnegie Mellon University.

What is Frank Joseph Daugherty's net worth?: The estimated net worth of Frank Joseph Daugherty is at least $1.14 million as of April 25th, 2022. Dr. Daugherty owns 90,121 shares of Greenwich LifeSciences stock worth more than $1,140,932 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Daugherty may own. Learn More about Frank Joseph Daugherty's net worth.
How old is Frank Joseph Daugherty?: Dr. Daugherty is currently 73 years old. There are 3 older executives and no younger executives at Greenwich LifeSciences. Learn More on Frank Joseph Daugherty's age.
How do I contact Frank Joseph Daugherty?: The corporate mailing address for Dr. Daugherty and other Greenwich LifeSciences executives is , , . Greenwich LifeSciences can also be reached via phone at 832-819-3232 and via email at [email protected]. Learn More on Frank Joseph Daugherty's contact information.
Has Frank Joseph Daugherty been buying or selling shares of Greenwich LifeSciences?: Frank Joseph Daugherty has not been actively trading shares of Greenwich LifeSciences during the last quarter. Most recently, on Monday, April 25th, Frank Joseph Daugherty bought 1,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $16.25 per share, with a total value of $16,250.00. Following the completion of the transaction, the insider now directly owns 90,121 shares of the company's stock, valued at $1,464,466.25. Learn More on Frank Joseph Daugherty's trading history.
Who are Greenwich LifeSciences' active insiders?: Greenwich LifeSciences' insider roster includes Frank Daugherty (Insider), Kenneth Hallock (Director), David McWilliams (Director), Snehal Patel (CEO), and Jaye Thompson (VP). Learn More on Greenwich LifeSciences' active insiders.
Are insiders buying or selling shares of Greenwich LifeSciences?: During the last year, Greenwich LifeSciences insiders bought shares 12 times. They purchased a total of 209,925 shares worth more than $2,988,219.50. The most recent insider tranaction occured on September, 26th when CEO Snehal Patel bought 1,500 shares worth more than $21,945.00. Insiders at Greenwich LifeSciences own 51.7% of the company. Learn More about insider trades at Greenwich LifeSciences.
Information on this page was last updated on 9/26/2024.

Frank Joseph Daugherty Insider Trading History at Greenwich LifeSciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/25/2022	Buy	1,000	$16.25	$16,250.00	90,121
12/14/2021	Buy	1,111	$26.99	$29,985.89
11/23/2020	Buy	1,000	$5.10	$5,100.00	87,010

Frank Joseph Daugherty Buying and Selling Activity at Greenwich LifeSciences

Greenwich LifeSciences Company Overview

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Today's Range

Now: $12.66

$12.66

$13.30

50 Day Range

MA: $13.87

$12.37

$15.29

2 Week Range

Now: $12.66

$8.00

$21.44

Volume

5,151 shs

Average Volume

39,635 shs

Market Capitalization

$166.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

JD Vance Predicts: Wall Street vs. Trump & Your Money

From Priority Gold | Ad